Want to see DMAC full AI Analyst Report?
DMAC Stock Chart & Stats
$6.74
$0.07(0.97%)
At close: 4:00 PM EDT
$6.74
$0.07(0.97%)
Day’s Range― - ―
52-Week Range$4.01 - $10.42
Previous CloseN/A
Volume23.88K
Average Volume (3M)233.78K
Market Cap
$340.54M
Enterprise Value$313.06
Total Cash (Recent Filing)$51.33M
Total Debt (Recent Filing)$212.00K
Price to Earnings (P/E)―
Beta1.50
Next Earnings
Aug 12, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.71
Shares Outstanding53,883,347
10 Day Avg. Volume180,430
30 Day Avg. Volume233,782
Financial Highlights & Ratios
PEG Ratio-0.68
Price to Book (P/B)6.66
Price to Sales (P/S)0.00
P/FCF Ratio-12.85
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$13.00Price Target Upside92.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.78
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial MomentumSurpassing 70% enrollment across ~70 activated sites materially derisks the stroke program vs early-stage peers. Sustained enrollment and a defined interim analysis framework increases the probability of timely readouts, supports partnering discussions and underpins long-term program optionality.
Conservative Balance Sheet / Low LeverageExtremely low debt reduces financial risk and preserves strategic flexibility for multi-year clinical development. With sizeable equity relative to liabilities, management can prioritize trial execution and selective partnering without near-term solvency pressure, supporting sustainable program funding choices.
Regulatory Progress Outside U.S.Health Canada approval enables a non-U.S. regulatory and enrollment pathway that diversifies program risk and accelerates global data generation. Progress in multiple jurisdictions increases trial redundancy, shortens overall development timelines, and strengthens the company’s ability to de‑risk programs for partners or regulators.
Bears Say
No Revenue; Widening Net LossesPersistent zero revenue and escalating net losses mean the business remains fully reliant on external financing or partnerships. Over time this raises dilution risk, places pressure on management to secure non-dilutive funding or deals, and leaves shareholder value dependent on clinical success rather than operating cash generation.
High And Growing Cash BurnQuarterly and TTM cash burn has increased alongside R&D expansion, eroding working capital and making the stated runway sensitive to trial pace or unexpected costs. Structural higher burn increases the likelihood of future capital raises, which can dilute stakeholders and complicate multi‑trial execution if financing windows tighten.
U.S. Regulatory Uncertainty And Extra Preclinical TestingAn FDA request for additional embryo/fetal studies and an adverse rabbit result create durable uncertainty for U.S. timelines. Additional preclinical work raises costs, could delay U.S. IND progress, and may necessitate further studies if regulators demand alternative models, complicating commercialization planning and partner negotiations.
Diamedica Therapeutics News
DMAC FAQ
What was Diamedica Therapeutics Inc’s price range in the past 12 months?
Diamedica Therapeutics Inc lowest stock price was $4.01 and its highest was $10.42 in the past 12 months.
What is Diamedica Therapeutics Inc’s market cap?
Diamedica Therapeutics Inc’s market cap is $340.54M.
When is Diamedica Therapeutics Inc’s upcoming earnings report date?
Diamedica Therapeutics Inc’s upcoming earnings report date is Aug 12, 2026 which is in 11 days.
How were Diamedica Therapeutics Inc’s earnings last quarter?
Diamedica Therapeutics Inc released its earnings results on May 06, 2026. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.186 by -$0.004.
Is Diamedica Therapeutics Inc overvalued?
According to Wall Street analysts Diamedica Therapeutics Inc’s price is currently Undervalued.
Does Diamedica Therapeutics Inc pay dividends?
Diamedica Therapeutics Inc does not currently pay dividends.
What is Diamedica Therapeutics Inc’s EPS estimate?
Diamedica Therapeutics Inc’s EPS estimate is -0.2.
How many shares outstanding does Diamedica Therapeutics Inc have?
Diamedica Therapeutics Inc has 53,883,347 shares outstanding.
What happened to Diamedica Therapeutics Inc’s price movement after its last earnings report?
Diamedica Therapeutics Inc reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.186. Following the earnings report the stock price went up 0.153%.
Which hedge fund is a major shareholder of Diamedica Therapeutics Inc?
Currently, no hedge funds are holding shares in DMAC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Diamedica Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.00 (92.88% Upside)
$13.00 (92.88% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.1%
Last 30 Days ▲ 2.9%
Last 30 Days ▲ 2.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
38.01%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
36.70%
Trailing 12-Months
Company Description
Diamedica Therapeutics Inc
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.
DMAC Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful clinical progress (stroke enrollment >70%, encouraging Phase II efficacy signals, Health Canada approval and active preeclampsia cohorts) and a clear pathway to multiple near-term clinical milestones through 2027. Financially, the company maintains a runway into 2027 but reported a quarter-over-quarter decline in cash, higher quarterly cash burn and materially higher R&D spend. Regulatory uncertainty in the U.S. (additional preclinical testing and an adverse rabbit study result) represents the primary risk to U.S. trial timelines. On balance, the clinical momentum and regulatory/operational achievements outweigh the financial and preclinical challenges at this stage.View all DMAC earnings summariesDMAC Stock 12 Month Forecast
Average Price Target
$13.00
▲(92.88% Upside)
Technical Analysis
Tvardi Therapeutics
―
Capricor Therapeutics
―
Rocket Pharmaceuticals
―
Benitec Biopharma
―
Annexon Biosciences
―
Ownership Overview
17.71% Insiders
2.86% Mutual Funds
― Other Institutional Investors
75.44% Public Companies and
Individual Investors